Chemical ID: CAS Formula HS Code Database — Cholesterol

Product Identification Item	Technical Data
Product Name & IUPAC Name	Cholesterol; CAS 57-88-5; IUPAC: (3β)-cholest-5-en-3-ol
Chemical Formula	C27H46O; molecular weight 386.65 g/mol
Synonyms & Trade Names	Cholest-5-en-3β-ol; cholesterin; cholesteryl alcohol. Trade names are grade- and supplier-specific; no single generic trade designation applies to the parent sterol.
HS Code & Customs Classification	HS 2906.13.00; customs classification: cyclic alcohol; sterol. Subheading 2906.13 covers sterols and inositols. National tariff schedules may differentiate by purity, source, and end use; confirmation with destination customs authority is required.

Cholesterol is supplied as a white to off-white crystalline powder or granular solid, with a faint characteristic sterol odor. The observed form depends on the crystallization, milling, and drying route: compendial and cosmetic grades are commonly supplied as fine crystalline powders, while technical material may be supplied as crystalline aggregates, flakes, or micronized solids. Melting range is typically 147–149 °C, with compendial acceptance ranges extending up to 150 °C. Boiling point is not practically applicable as a distillation value; thermal decomposition occurs near 360 °C before a defined boiling point can be recorded. Flash point is not assigned for the solid product because the material decomposes rather than volatilizing; however, fine cholesterol dust shares the combustible-dust hazards of many organic powders. Density is approximately 1.052 g/cm³ at 20 °C; bulk density is grade- and milling-dependent and affects hopper flow, dust generation, and blending efficiency. Chemical stability is governed primarily by the unsaturated sterol skeleton. The C5–C6 double bond and the allylic C7 position are the main oxidative entry points. Prolonged exposure to atmospheric oxygen, light, elevated temperature, or trace transition metals promotes autoxidation to cholesterol oxidation products, principally 7-ketocholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 5α,6α-epoxycholesterol, 5β,6β-epoxycholesterol, and cholestane-3β,5α,6β-triol. These products are measurable by HPLC and are the critical degradation markers used in batch release and stability evaluation. Strong acid or rigorous dehydration conditions can convert the 3β-alcohol to cholesta-3,5-diene, while the hydroxyl group participates readily in esterification and etherification. The material is not considered self-reactive, but fine particulate dispersions in air require housekeeping and grounding controls. Solubility follows the sterol character: practically insoluble in water, soluble in chloroform, diethyl ether, and hot acetone, moderately soluble in ethyl acetate, and sparingly soluble in cold ethanol. Solution preparation for analytical or formulation work commonly uses chloroform, chloroform/methanol, or warmed ethanol; cholesterol solutions should be prepared under nitrogen or argon and protected from light because oxidation kinetics accelerate when the crystalline lattice is disrupted. For aqueous cell-culture or biopharmaceutical protocols, direct dissolution is not practical; water-compatible delivery typically requires pre-dissolution in ethanol followed by complexation with methyl-β-cyclodextrin or dispersion with a stabilized carrier system. Prolonged heating above 60 °C is not recommended unless justified by the process, because it promotes degradation without substantially improving dissolution once the solvent limit is reached.

How Are Specification Limits and Purity Profiles Set Across Commercial Grades?

The specification framework is deliberately graded because cholesterol crosses industrial, cosmetic, pharmaceutical, and diagnostic boundaries. Technical grade material is generally defined by sterol content and gross impurity limits; cosmetic grade introduces tighter related-sterol and color criteria; pharmaceutical/compendial grade adds identity, specific rotation, heavy-metal, residual-solvent, and related-substance controls based on the applicable compendial monograph. The table below is a representative commercial specification structure rather than a universal release specification. Final release limits are grade-, route-, and customer-specific and are controlled in the internal specification register.

Parameter	Technical grade	Cosmetic grade	Pharmaceutical/compendial grade
Appearance	white to off-white powder or granules	white to faint yellow crystalline powder	white or almost white crystalline powder
Identification	IR; melting point	IR; melting point; TLC	IR; melting point; specific rotation; chromatographic identity
Assay, GC-FID area%, anhydrous basis	≥ 95.0%	≥ 98.0%	≥ 99.0% or 97.0–102.0% according to monograph
Melting range	147–149 °C	147–149 °C	147–150 °C
Loss on drying	≤ 0.5%	≤ 0.3%	≤ 0.3%
Related sterols, HPLC	reporting	lanosterol and dihydrolanosterol ≤ 0.5% total	individual unspecified ≤ 0.10%; total ≤ 0.5%
Residual solvents	controlled according to supplier/IP release	≤ 0.5% total	compendial and ICH Q3C criteria
Heavy metals	≤ 20 ppm	≤ 10 ppm	≤ 10 ppm or ICH Q3D element-specific limits
Residue on ignition/sulfated ash	≤ 0.2%	≤ 0.1%	≤ 0.1%
Microbial limits	not routinely specified	TAMC ≤ 100 CFU/g when relevant	compendial or customer monograph criteria

The impurity profile of wool grease-derived cholesterol is dominated by biosynthetically related sterols: lanosterol, dihydrolanosterol, desmosterol, 7-dehydrocholesterol, and trace unsaturated sterols. Oxidation impurities arise during storage and processing and are tracked separately from process-related impurities. For high-purity release, related substances are commonly determined by GC-FID after trimethylsilyl derivatization or by HPLC with evaporative light scattering or charged aerosol detection. Residual solvents are measured by headspace GC according to compendial general methods such as Ph. Eur. 2.4.24 or USP <467>. Elemental impurities are measured by ICP-MS within ICH Q3D risk-assessment workflows. Identity is confirmed by infrared absorption against a reference standard, melting behavior, and specific rotation where the monograph requires it. Compendial-purity cholesterol is recovered predominantly from wool grease rather than produced by total chemical synthesis. The extraction route is selected because wool grease contains a sterol fraction that can be processed at commercial scale using well-understood saponification, extraction, crystallization, and chromatographic steps. Total synthesis is not a standard industrial route due to the complexity of the tetracyclic sterol framework and the cost disadvantage relative to natural-source purification. Fermentation-derived cholesterol has been demonstrated but is less common in compendial supply chains, where regulatory filing history and established impurity profiles favor the wool grease route. Raw material selection begins with lanolin or crude wool grease having an acceptable sterol content, low free-acid burden, controlled pesticide and veterinary drug residue profile, and low heavy-metal content. The base used in saponification is typically sodium hydroxide or potassium hydroxide in an aqueous alcohol system. Extraction solvents are selected for sterol solubility and phase separation, commonly hydrocarbon or chlorinated solvents in older systems, with modern processes favoring recoverable solvent blends chosen to reduce residual-solvent risk. Activated carbon may be used for decolorization and removal of polar oxidative color bodies. The first chemical operation is alkaline saponification of lanolin esters. The wool grease triglycerides and sterol esters are hydrolyzed to fatty acid salts and free sterols. The unsaponifiable sterol fraction is then separated by solvent extraction. Process control points include saponification temperature, agitation, reaction completeness, phase disengagement, solvent-to-sterol ratio, water content, and inert-gas blanketing. After extraction, cholesterol is concentrated by cooling crystallization. Separation of cholesterol from lanosterol and dihydrolanosterol is the main purification challenge because of similar solubility behavior; repeated crystallization from methanol, ethanol, or acetone-water systems is used to raise sterol purity. For high-purity grades, preparative chromatography or selective precipitation may be required to reduce related sterols and oxidation products to compendial limits. In-process control includes sterol-profile monitoring by GC or HPLC after saponification and after each crystallization stage, Karl Fischer water content of the wet cake, solvent content before drying, and visual/color assessment. Final drying is conducted under vacuum at controlled temperature to preserve melting behavior and minimize oxidation. Batch release testing includes identity, assay, related sterols, residual solvents, loss on drying, residue on ignition, heavy metals, and microbial/endotoxin parameters where the intended use requires them. Batch consistency is managed through defined raw-material lots, fixed crystallization temperature curves, controlled drying profiles, and shipment under nitrogen or argon blanketing.

Derivatization Chemistry and Typical Reaction Windows

The 3β-hydroxyl group and the C5–C6 double bond define most commercial derivatization pathways. The hydroxyl group is esterified with fatty acids, acetic anhydride, or acid chlorides to produce cholesteryl esters used in cosmetic emulsions, liquid-crystal formulations, and analytical standards. Esterification is typically performed in dichloromethane, toluene, or pyridine at 0–25 °C, using a base catalyst such as pyridine, triethylamine, or 4-dimethylaminopyridine. Reaction completeness is monitored by TLC or GC, and excess reagent is removed by aqueous washing or distillation. Oxidation at the allylic C7 position proceeds through radical or singlet-oxygen mechanisms and yields 7-hydroperoxides, which rearrange to 7α-hydroxycholesterol, 7β-hydroxycholesterol, and 7-ketocholesterol. This chemistry is relevant both as a degradation pathway and as a preparative route to oxidized sterol reference compounds. Hydrogenation of the C5–C6 double bond over palladium or platinum catalysts converts cholesterol to cholestanol, with reaction pressure and solvent polarity adjusted to limit over-reduction by-products. Epoxidation with meta-chloroperbenzoic acid or peracetic acid gives 5α,6α- and 5β,6β-epoxides, which are intermediates in further ring-opening transformations. Downstream products include cholesterol esters for cosmetic and pharmaceutical formulation, cholesteryl acetate and cholesteryl oleate as liquid-crystal intermediates, 7-dehydrocholesterol as the immediate precursor for vitamin D3, cholestanol as a reference sterol, and cholesterol-derived polyoxyethylene ethers for specialized colloid applications. Bile acid derivatives can be accessed through oxidative side-chain degradation, although that route is not normally operated at the cholesterol purification site unless integrated with downstream steroid manufacturing.

Storage Envelope, Packaging Compatibility, and Shelf-Life Criteria

Storage recommendations follow directly from the oxidation chemistry documented above. High-purity and compendial grades are assigned storage at 2–8 °C where extended shelf life is required, while technical and some cosmetic grades may be stored at ≤25 °C in a dry, light-protected warehouse. Humidity should be controlled to avoid water uptake and caking; storage above 60% RH is not recommended unless the container is sealed and desiccated. The crystalline solid should be protected from direct sunlight and strong artificial UV sources. For long-term retention, containers are flushed with nitrogen or argon, and opened packages should be resealed under inert gas. Container compatibility is acceptable with high-density polyethylene drums with low-density polyethylene liners, fiber drums with sealed polymer liners, amber glass bottles for small analytical quantities, and aluminum foil laminate pouches for oxygen-sensitive high-purity material. Uncoated steel and copper alloys should be avoided for long-term storage because metal ions accelerate autoxidation. Bulk silos are not typical for high-purity cholesterol due to oxidation, dust explosion, and cross-contamination risk. Shelf life is assigned from stability data and is commonly 24–36 months for unopened containers under the recommended storage conditions, depending on grade, container type, and regulatory jurisdiction. Degradation signs include visible yellowing or browning, a distinct oxidative off-odor, caking, melting-range depression or broadening, and an increase in 7-ketocholesterol and total related sterols by HPLC. A batch should not be released or repackaged if oxidative marker values exceed the registered specification, even when visible appearance remains acceptable.

When Handling Micronized Cholesterol in Production: Hazard and Exposure Controls

Cholesterol is not classified as acutely toxic under EC 1272/2008 or equivalent GHS systems. No harmonized hazard statement is assigned for the solid substance itself. The principal industrial hazards are airborne dust exposure and combustible dust accumulation. Handling operations that generate fine dust should use local exhaust ventilation, grounded transfer lines, and inert-gas padding where feasible. Dry sweeping should be replaced by HEPA-filtered vacuum removal to prevent dust clouds and secondary dust accumulation on horizontal surfaces. Published data for cholesterol-specific dust explosion parameters is limited, so the conservative approach applied to fine organic powders is recommended. General particulate not otherwise classified exposure limits may be used as a screening reference: ACGIH PNOC values of 10 mg/m³ inhalable and 3 mg/m³ respirable are commonly applied where no cholesterol-specific occupational exposure limit exists. Air monitoring should target total and respirable dust during milling, sieving, and repacking. Respiratory protection with a P2 or P3 particulate filter is appropriate when engineering controls cannot keep airborne dust below the screening limit. Precautionary measures for laboratory and production staff include nitrile gloves, safety glasses, and protective clothing to avoid skin and eye contact with the dry powder. In case of eye contact, rinse with water and remove contact lenses if present. Spills should be contained and collected with non-sparking tools and HEPA vacuum equipment. Waste disposal must comply with local regulations for organic solid waste; release to waterways or municipal drainage is not acceptable. No chronic organ-specific target toxicity is assigned for cholesterol under GHS, but the oxidation products may carry biological activity and should be controlled in high-purity and pharmaceutical grades.

Cholesterol available from this production site is derived from wool grease/lanolin via saponification of lanolin esters, extraction of the unsaponifiable fraction, and subsequent solvent purification. Production capacity is allocated through a campaign-based schedule in a multipurpose GMP suite; therefore capacity is not expressed as a single fixed annual tonnage. Campaign duration depends on the number of recrystallization or column chromatography passes required for the assigned grade, cleanout validation between technical and low-endotoxin material, and analytical release load. Low-endotoxin, low-peroxide, and cell-culture-tested lots require additional purification operations and controlled packaging, which lowers throughput relative to technical or cosmetic material. Availability is controlled through quarterly production planning, with uncommitted volume limited for high-specification grades because those campaigns occupy dedicated equipment trains and cannot be interleaved with standard technical material without cleaning verification.

Lead time and minimum order quantity are grade-specific rather than universal. Compendial material can be confirmed against scheduled production slots, while low-endotoxin, cell-culture, or custom residual-solvent grades may require a dedicated campaign and longer release time because of additional in-process sampling and final endotoxin/residual solvent testing. The minimum order quantity is set by the packaging configuration, the cleaning burden associated with the requested grade, and the analytical certificate scope; trial quantities may be available only from retained reference material and are not necessarily representative of full commercial campaign economics.

Packaging configurations are assigned by grade and transport stability data.

• 25 kg net HDPE drum with double food-grade PE liner for compendial and technical material.
• 10 kg net aluminum-laminated vacuum bag inside a fiber drum for low-endotoxin, cell-culture, and oxygen-sensitive grades; cold chain is applied when shelf-life data require it.
• 500 g or 1 kg analytical sample containers for method qualification and customer trial work.

Shipping is arranged under customer-specific Incoterms. The standard document set includes certificate of analysis, SDS, TSE/BSE declaration, allergen statement, residual solvent declaration where applicable, and batch-specific label reconciliation. Payment terms are transaction-specific; initial cross-border orders commonly require an irrevocable at-sight letter of credit, while established supply agreements may operate on documented T/T terms. Blanket credit is not offered without a signed quality agreement and completed site audit. Controlled grades are packed in sealed containers because moisture uptake can lower flowability and affect downstream weighing in pharmaceutical compounding.

Raw material cost composition is dominated by the lanolin/wool grease input, solvent consumption, energy for distillation and solvent recovery, and quality control burden. The unsaponifiable fraction yield and solvent recovery rate are key internal cost variables. Compendial-grade release testing includes related sterol profiling by gas chromatography, residual solvent determination by headspace GC, and endotoxin by LAL for controlled grades; these costs are allocated across campaign batches and increase with sampling density. In-process control after each recrystallization or chromatography pass includes melting-range determination and a chromatographic sterol-profile comparison against a qualified working standard. Final release testing is grade-dependent and may include monograph-specific identity, organic purity, loss on drying, residue on ignition, residual solvents, and endotoxin for controlled-burden grades. The final release standard is subject to internal quality control criteria and customer requirements, not solely nominal sterol content.

Fluctuation in raw material prices is primarily tied to wool grease/lanolin supply, which is a by-product of wool processing and therefore not fully elastic to cholesterol demand. Additional causes include petrochemical-linked solvent and energy prices, logistics delays, import/export documentation holds, and pharmacopoeial changes that alter purification yield. Regulatory changes to related sterol or residual solvent limits can increase production cost without a change in lanolin input price, because additional purification passes reduce yield and increase solvent recovery burden.

Grade, purity, and packaging certification do not affect price as a simple linear function of sterol content. A technical/cosmetic lot requires fewer purification passes and a narrower release file than compendial material. Ph. Eur. and other compendial material add monograph-specific identity, organic purity, sterol profile, loss-on-drying, and residue-on-ignition testing. Low-endotoxin cell-culture grade adds depyrogenation, controlled packaging, and longer release. Packaging certification also drives cost: food-grade PE liner qualification, low-particulate drum supply, vacuum sealing, and validated cold chain each carry separate handling and qualification costs. A lot that is simultaneously compendial, low-endotoxin, and packed in a validated low-particulate format will therefore carry a higher price than a technical bulk lot of the same nominal sterol content.

US, EU, Japan, India and China Supply-Demand Balances Through 2026

Global demand for cholesterol is concentrated in vitamin D3 precursor synthesis, with additional demand from pharmaceutical intermediates, cell-culture media, and cosmetic/personal care applications. The vitamin D3 chain is the highest-volume segment and is concentrated in China and India. Pharmaceutical and cell-culture grades are smaller in volume but are sensitive to endotoxin, residual solvent, and documentation requirements. High-purity low-endotoxin supply is more constrained than technical supply because fewer production sites operate segregated low-burden trains and validated packaging areas.

China holds the largest integrated lanolin-to-cholesterol supply position. Domestic demand is driven by vitamin D3 manufacturing and pharmaceutical intermediates; environmental enforcement and solvent recovery improvements are the main cost variables. India is a significant vitamin D3 converter and sources cholesterol either as imported high-purity material or less-purified intermediate for onward conversion; import logistics and pharmacopoeia alignment are key supply constraints. The United States demand is concentrated in pharmaceutical excipient, cell-culture, and research-grade applications, where DMF availability, cold chain documentation, and low-endotoxin data are as important as the sterol profile. EU demand centers on Ph. Eur.-compliant pharmaceutical and cosmetic material with REACH-registered supply lines and BSE/TSE assurance. Japan maintains a smaller high-purity JP-grade market with a restricted supplier base and exacting residual solvent and related sterol expectations.

The 2026 price trend is assessed as stable-to-firm. Upward pressure is expected from lanolin supply tightness, solvent and energy cost pass-through, and stricter compendial impurity and reporting expectations. Downward risks include new integrated capacity in China, weaker vitamin D3 converter demand, or substitution to non-compendial technical grades where regulatory frameworks allow. Point-level price forecasts across different grades are not technically defensible because contract pricing is non-public and regional grade mix varies. Published data for contracted price formation is limited; the forecast is therefore a directional supply-demand assessment rather than a numeric projection.

Data sources include public customs statistics for wool grease/lanolin and cholesterol trade, pharmacopoeia revision notices, manufacturing site audit observations, logistics provider guidance, and exchange-reported solvent and energy price indices. The methodology applies grade-level supply-demand triangulation. Limitations include transfer pricing in related-party trade, non-public contract terms, and differences in national regulatory acceptance.

When Pharmacopoeia Changes and BSE/TSE Documentation Requirements Alter Global Shipments

Recent market developments include tightening availability of wool grease/lanolin-derived raw material as wool processing volumes shift across regions. Controlled-burden cholesterol demand has increased in cell-culture and lipid-based formulation development, placing additional pressure on suppliers with validated low-endotoxin processing capability. Vitamin D3 converter buying remains price-sensitive, producing a two-speed market between high-volume technical material and high-specification controlled grades.

Regulatory compliance updates affecting cholesterol supply include pharmacopoeial monograph revisions for related sterols, residual solvents, and storage conditions. Compliance with USP-NF, Ph. Eur., JP, and ChP monographs requires grade-specific analytical method validation and stability documentation. EU customers often require REACH-registered supply lines and BSE/TSE assurance reflecting the wool-grease origin. US pharmaceutical customers frequently request a drug master file or equivalent technical package before first qualification. These documentation requirements can delay shipment even when material is physically available.

Supplier response has focused on multi-source lanolin qualification, long-term wool grease supply agreements, and campaign segregation to prevent cross-contamination between low-endotoxin and technical material. Internal control measures include batch-specific sampling after recrystallization, residual solvent monitoring before release, and packing-area environmental monitoring for controlled grades. Pre-shipment document review covers BSE/TSE, origin, allergen, and residual solvent statements to reduce customs and regulatory holds.

Cholesterol is supplied as a polycyclic sterol of the cholestane series, with a secondary hydroxyl at C-3 and a double bond at C-5/C-6. The product’s application-relevant behavior is governed less by gross chemical identity than by the quantitative profile of co-occurring sterols, oxidation products, residual solvents, microbial load, and endotoxin content. A grade designation therefore identifies a control set matched to a downstream unit operation, not a single purity value.

Application Fields and Grade Matching Guide

In pharmaceutical and biopharmaceutical manufacturing, cholesterol functions as a bilayer-ordering component in liposomes, lipid nanoparticles, and parenteral emulsions. In liposomal formulations, it is typically incorporated at 30–50 mol% of total bilayer lipid, where it reduces membrane permeability and increases packing order of phospholipid acyl chains. However, 7-ketocholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, cholesterol 5α,6α-epoxide, and cholestane-3β,5α,6β-triol are more polar than cholesterol and alter membrane anchoring. Consequently, compendial pharmaceutical grades are specified by low related-sterol and oxidation-product profiles rather than by total sterol assay alone.

Cell culture and biotechnology applications require an ethanol-soluble lipid supplement that supports cholesterol-dependent membrane synthesis in serum-free or chemically defined media. Lot acceptance for these grades focuses on endotoxin, mycoplasma, bioburden, and origin documentation, because lipopolysaccharide contamination can activate macrophage-related cell lines and confound cell-based assays. Animal-origin statements and TSE/BSE risk assessment under Ph. Eur. 5.2.8 are common release documents.

Cosmetic and personal-care applications use cholesterol as a lipophilic emollient and consistency-modifying agent in anhydrous and emulsion systems. The primary grade differentiators are color, odor, residual solvent character, heavy-metal content, and oxidation markers under EC 1223/2009 and REACH obligations.

Vitamin D3 and downstream steroid chemistry employ technical grades in which related sterols, cholestanol, and desmosterol are tolerable if the subsequent photochemical or chromatographic sequence separates them. Water content, ash, and solvent profile affect downstream yields and catalyst life more than trace oxidation products do.

Analytical and diagnostic workflows use cholesterol as a substrate or calibration material for cholesterol oxidase/cholesterol esterase-based assays, requiring lot-to-lot consistency in chromatographic purity and relative response rather than compendial microbial limits.

Application field	Typical grade designation	Primary release drivers
Liposomal and lipid nanoparticle formulation	Pharmaceutical/compendial grade	Oxidation marker profile, related sterols, endotoxin, bioburden, residual solvents, elemental impurities
Serum-free cell culture	Cell culture grade	Endotoxin, mycoplasma, origin statement, ethanol solubility, bioburden
Cosmetic emulsions and skin conditioning	Cosmetic grade	Color, odor, heavy metals, oxidation markers, microbial limits
Vitamin D3 and steroid intermediate synthesis	Technical/industrial grade	Total sterol assay, related-sterol tolerance, moisture, residue on ignition, solvent profile
Analytical reference and enzymatic substrates	High-purity/chromatographic standard	Chromatographic purity, identity, assay against certified reference, lot-to-lot uniformity

Application field	Critical parameter	Typical control method or rationale
Liposomal/LNP	Oxidation products: 7-ketocholesterol, 7α/β-hydroxycholesterol, 5α,6α-epoxide, triol	HPLC with UV or charged aerosol detection; limit set by compendial or customer specification
Cell culture	Endotoxin and mycoplasma	LAL per Ph. Eur. 2.6.14 or USP <85>; mycoplasma per Ph. Eur. 2.6.7
Cosmetic	Color/odor and oxidation markers	Visual or Gardner/Lovibond color; peroxide value where applicable; headspace GC for residual solvents
Vitamin D3 synthesis	Related sterol distribution and water	GC or HPLC sterol profile; Karl Fischer titration; residual solvent by headspace GC
Analytical/diagnostic	Purity and identity	Melting range by Ph. Eur. 2.2.14; specific rotation by Ph. Eur. 2.2.7; HPLC purity against certified reference

Because the C-5/C-6 double bond is susceptible to autooxidation, processing conditions and packaging exert greater influence on liposomal and cell-culture grades than on industrial intermediates. Formation of 7-ketocholesterol and epoxide derivatives introduces polarity changes that weaken sterol–phospholipid association. Production-scale drying and micronization are therefore executed under vacuum or nitrogen with exclusion of light. Bulk material is commonly packaged in double polyethylene bags inside aluminum foil or fiber drums, and trace-metal exposure from equipment is assessed for iron, copper, and chromium because these ions accelerate autoxidation.

Route selection also determines the impurity profile. Lanolin-derived material is obtained by saponification of wool grease and subsequent solvent fractionation; it may retain cholestanol and desmosterol unless additional recrystallization or derivatization-based purification is applied. Synthetic or biotransformation-derived cholesterol may be selected when customer specifications prohibit animal-origin raw materials. Residual solvent profiles are therefore method-defined and must be evaluated against ICH Q3C; elemental impurity levels are assessed against ICH Q3D for compendial grades.

How to Select the Right Grade

1. Step 1: Define Application — Determine whether cholesterol is used as a pharmaceutical excipient, cell-culture supplement, cosmetic ingredient, chemical intermediate, or analytical reference. This decision sets compendial, microbial, and packaging requirements.
2. Step 2: Identify Regulatory Requirements — Compare the relevant monograph or regulation. For pharmaceutical and liposomal use, apply the current Ph. Eur./USP-NF monograph and cGMP expectations. For parenteral or cell-culture use, include endotoxin and mycoplasma testing. For cosmetics, apply EC 1223/2009 and REACH. For industrial synthesis, confirm national chemical inventory and site permit obligations.
3. Step 3: Evaluate Purity Needs — Define the analytical profile beyond total assay. For lipid nanoparticle applications, specify limits for cholestanol, desmosterol where relevant, and oxidation markers, because these affect bilayer packing and may be more important than gross purity. Technical applications may tolerate higher related-sterol levels. The final release standard is subject to internal quality control criteria and customer requirements.
4. Step 4: Consider Volume & Budget — High-purity compendial grades often require additional recrystallization or chromatographic purification, increasing cost and lead time. Large-volume industrial use should compare the cost of downstream purification in the customer’s process against the cost of purchasing a higher grade.
5. Step 5: Request Sample for Validation — Obtain a representative sample from production lots, not pilot or laboratory preparation, and test in the intended formulation matrix or reaction sequence. Include accelerated oxidation or solubility checks, confirm compatibility with the final analytical method, and request a certificate of analysis plus origin/TSE documentation when required.

Trust & Compliance: Quality Certifications & Procurement Support for Cholesterol

Cholesterol released from this manufacturing site is controlled as a compendial-grade, technical-grade, or research-grade sterol depending on the declared application and the purchasing specification. The batch release file connects raw material origin, purification method, in-process sterol profile, drying parameters, and final QC results. Because the impurity profile is route-dependent, no single universal limit set applies; limits for related sterols, residual solvents, elemental impurities, and drying loss are assigned by grade, monograph edition, and target jurisdiction.

Quality Management Certifications, Audit Scope, and Release Documentation

The site quality management system is certified to ISO 9001:2015. Manufacturing, storage, and dispatch are audited against internal procedures for supplier evaluation, change management, nonconformance handling, corrective action, and batch release. Pharmaceutical-grade campaigns that require GMP controls are conducted under quality system elements aligned with ICH Q7; this applies only to grades where the customer registration or compendial status requires GMP. Environmental and occupational health management follow ISO 14001:2015 and ISO 45001:2018 where site certificates are in force.

Documentation and reports are grade-specific. Standard release documentation includes:

• Certificate of Analysis: batch number, manufacturing date, retest or expiry date where assigned, specification reference, method code, limit, and result for each test.
• Safety Data Sheet: hazard classification according to current GHS and applicable regional regulation; storage and spill handling.
• Residual solvent report: headspace GC results compared to ICH Q3C or current pharmacopoeial limits for the declared grade.
• Elemental impurity statement: risk-based evaluation aligned with ICH Q3D or USP 232/233, grade-dependent.
• Origin statement: wool grease-derived or alternative qualified source; TSE/BSE documentation where applicable.
• Allergen and GMO statements where requested; these are site- and grade-specific.

Quality compliance matrix for cholesterol grades

Area	Standard / reference	Scope and application
Quality management	ISO 9001:2015	Supplier control, change management, CAPA, batch release
Pharmaceutical GMP alignment	ICH Q7	Pharmaceutical-grade campaigns where required
Compendial release	USP-NF, Ph. Eur., JP, ChP	Grade-specific monograph tests
Residual solvents	ICH Q3C, Ph. Eur. 2.4.24	Headspace GC release report
Elemental impurities	ICH Q3D, USP 232/233	Risk-based control, route and grade dependent
TSE/BSE	EMA/410/01 Rev. 3 or current	Raw material origin and extraction process documentation

Which Product-Specific Certifications Apply to Cholesterol Grades?

Cholesterol is available in multiple compendial grades, but not every grade is registered under every pharmacopoeia. The applicable specification is based on current monograph text of USP-NF, Ph. Eur., JP, or ChP where the site holds the relevant regulatory status. Compendial tests typically include identification, melting range, specific rotation, loss on drying, residue on ignition, acidity, related sterols, and residual solvents; the exact test list and acceptance limits follow the current edition cited in the batch release specification. Internal release limits may be tightened in a customer-spec annex only when the change is controlled by change management and does not conflict with the registered monograph.

Kosher and Halal certification are product- and site-specific; they are not automatically available for every shipment. A certificate can be supplied only when the marketed grade, production line, and current third-party certificate are aligned. Pharmaceutical excipient dossiers, GMP certificates, and site master file extracts are available under confidentiality agreement for qualification audits. The sterol source is qualified as either wool grease-derived or non-animal-origin; this is declared in the origin statement. If a customer requires synthetic cholesterol, the registration status and availability must be confirmed separately because it follows a different route and impurity profile.

Purchase Cooperation Instructions: Capacity, Sampling, and Supply Flexibility

Supply planning is campaign-based. Production capacity is governed by raw material fractionation, saponification/extraction throughput, crystallization cycles, solvent recovery rate, and drying capacity. The site uses shared equipment for multiple sterol grades, so availability is reserved against a rolling production plan. Forecast sharing is used to lock equipment time and to schedule solvent regeneration between campaigns. A stable production capacity supply and flexible business cooperation plan is therefore defined by the interaction of forecast volume, batch size, grade changeover frequency, and cleanout validation, not by a single plant nameplate number.

Core production capacity and stable supply capability are supported by closed stainless steel crystallization and vacuum drying equipment. In-process control includes sterol purity monitoring by GC or HPLC, related sterol profile, residual solvent drying endpoints, and loss on drying. Final batch homogenization and sampling follow a defined plan; the retained sample is maintained according to the site protocol. Multiple downstream packaging lines allow a released batch to be subdivided into different pack sizes without reprocessing. Stability of supply is further supported by qualification of more than one crude cholesterol source where applicable and by campaign planning that avoids simultaneous overhaul of critical utility systems.

Sample application and qualification sequence

Step	Required input	Manufacturer / QC action
1. Inquiry	Grade, quantity, intended use, target market, compendial requirement	Confirm available registration status and reference specification
2. Sample preparation	Customer specification or default grade	Draw sample from a released production-representative batch; homogenize and split
3. Dispatch	Destination, import permit, courier preference	Issue sample CoA, SDS, and origin/TSE statement if applicable
4. Evaluation	Customer QC results, application feedback	Compare with CoA; investigate any discrepancy; retain sample according to protocol

Detailed explanation of flexible cooperation mode is defined by the following supply options:

• Standard grade spot supply: purchase order against an existing released grade; release is made against internal or compendial specification.
• Annual framework agreement: forecast volume with tolerance band, reserved equipment time, and raw material allocation.
• Customer-spec annex: defined particle-size target, packaging, labeling, and supplementary tests; applied after first qualification.
• Toll purification: customer-supplied crude cholesterol is technically evaluated before campaign; purification route is set to target purity and impurity profile; output released under agreed specification.
• Custom process development: non-compendial research grade or specialized sterol fraction; controlled through development batch records.

Each mode is constrained by cleaning validation, batch changeover, compendial registration, and shelf-life or retest considerations where applicable. Toll processing and custom development require technical disclosure of the customer’s impurity profile and intended application to avoid cross-contamination risk and to confirm feasibility. Customer-specific packaging or labeling changes are processed through the site change control system before the first dispatch.

Current research and development activity for pharmaceutical-grade cholesterol is driven by three interacting demands: tighter sterol impurity control for lipid nanoparticle and cell culture applications, reduced oxidation markers during drying and storage, and sourcing diversification away from single animal-derived raw material streams. The main R&D hotspots center on purification of wool grease-derived sterols to consistently low lanosterol and 7-dehydrocholesterol contents, production of low-endotoxin and low-peroxide grades, and continuous chromatographic alternatives to repeated batch recrystallization. Process development work is focused on reducing the number of unit operations in which the C5–C6 double bond is exposed to oxygen and light; 7-ketocholesterol and 5,6-epoxycholesterol are monitored because they affect downstream formulation color, peroxide value, and pharmacopoeial compliance. Published data for specific proprietary continuous chromatography configurations is limited, but industrial interest is directed at countercurrent separation and preparative purification sequences that lower solvent inventory.

Emerging applications include use as a structural lipid in mRNA/LNP formulations, as a supplement in serum-free and chemically defined cell culture media for biomanufacturing, as a calibration substrate in enzymatic cholesterol diagnostic systems, and as a lamellar-phase component in skin barrier repair formulations. In barrier repair systems, a 3:1:1 molar ratio of cholesterol:ceramide:fatty acid is frequently used to align with the stratum corneum lipid matrix. For LNP-related work, customers typically define endotoxin limit, peroxide value, particle size after formulation, and vehicle solubility requirements before lot reservation because these parameters are more sensitive than bulk assay alone.

Technical challenges include separation from lanosterol and dihydrolanosterol, which co-crystallize with cholesterol due to similar sterol ring geometry; control of residual solvents in multi-solvent recrystallization trains; removal of animal-derived process impurities while maintaining TSE-relevant documentation; and stabilisation of dry powder against oxidation during milling, storage, and transport. Breakthroughs reported across the sterol field involve continuous chromatographic purification, supercritical CO₂ extraction at pilot scale, and enzymatic protection of the C3 hydroxyl group to allow selective removal of non-target sterols. The manufacturer evaluates these routes against purification yield, solvent inventory, and the ability to meet current Ph. Eur. and USP-NF impurity tables.

What Downstream Demand Signals Indicate for the 3–5 Year Horizon

Published third-party market projections for pharmaceutical-grade cholesterol and related sterol excipients vary by sourcing, pharmacopoeial status, and region; no single CAGR applies uniformly across grades. The 3–5 year market forecast is therefore assessed through grade-specific demand indicators. High-purity, low-endotoxin, GMP-documented cholesterol for lipid nanoparticle and cell culture applications is expected to show stronger demand than technical-grade material tied to steroid API and cosmetic intermediate economics. Supply security is linked to the wool grease chain, where cholesterol is recovered as a co-product of wool scouring rather than dedicated animal processing, and to the regulatory burden of maintaining TSE/BSE and residual solvent documentation under ICH Q3C.

Technological evolution is orientated toward continuous or semi-continuous purification with process analytical technology. Inline sterol profile monitoring, near-infrared moisture detection after vacuum or spray drying, and automated solvent recovery loops are considered key modernization points. Route changes, whether from batch crystallization to continuous chromatography or from single-solvent to mixed-solvent trains, must be bridged by impurity profile comparison under ICH Q7 and customer change notification obligations.

Sustainability and green chemistry improvements under evaluation include recovery and reuse of crystallization solvents, valorization of lanosterol and dihydrolanosterol byproduct streams, and replacement of halogenated complexation solvents with alternative extraction or biocatalytic steps. Supercritical CO₂ extraction is assessed for crude enrichment, but pharmacopoeial acceptance, residual solvent limits under ICH Q3C, and TSE safety documentation constrain the speed of route changes. Life cycle considerations favor raw material from existing wool scouring operations, where cholesterol is part of a byproduct valorization chain.

Technical Support and After-Sales Commitments in Sterol Supply

Technical consultation covers grade selection against the intended route of administration, analytical profile alignment, and regulatory documentation. The manufacturer provides batch-specific certificates showing sterol profile, residual solvent profile, elemental impurity statement according to ICH Q3D, microbial limits, and where applicable TSE/BSE compliance according to Ph. Eur. 5.2.8. Customers requesting lipid nanoparticle grades are asked to define endotoxin limit, peroxide value, particle size after formulation, and vehicle solubility requirements before lot reservation because these parameters are application-sensitive.

Application optimization support is offered as joint development work under confidentiality agreement. For lipid nanoparticle formulations, support may include premelting temperature control, ethanol dilution compatibility, and oxidation marker trending during accelerated storage. For cell culture applications, support focuses on dissolution in ethanol or cyclodextrin, sterile filtration throughput, and lot-to-lot consistency of low-endotoxin and low-particulate grades. For steroid synthesis, support includes residual solvent and water content alignment with downstream catalytic steps and avoidance of incompatible metal catalysts.

After-sales commitments include retention of reserve samples for the full retest period, batch traceability from wool grease lot through release, change notification before route or raw material changes, and complaint investigation under the quality system. The manufacturer maintains documentation according to ISO 9001:2015 and pharmaceutical-grade operations aligned with ICH Q7. The matrix below summarizes typical support items; customer-specific quality agreements may define additional parameters.

Documentation / support item	Scope	Reference / basis
Certificate of analysis	Assay, related sterols, loss on drying, residue on ignition, microbial limits	Current Ph. Eur. / USP-NF monograph
Residual solvent statement	Class 1/2/3 solvent profile	ICH Q3C
Elemental impurity statement	Risk-based metal profile	ICH Q3D
TSE/BSE statement	Raw material origin and exposure risk	Ph. Eur. 5.2.8
Stability summary	Retest period under specified storage	ICH Q1A(R2)
Change notification	Route/source/specification changes	ICH Q7

This matrix is not exhaustive; additional parameters may be defined in customer-specific quality agreements or regulatory dossiers.

Cholesterol NF and Technical Grades: Production, Control, and Industrial Applications

Cholesterol (CAS 57-88-5; C₂₇H₄₆O; molecular mass 386.65 g/mol) is manufactured at the production site in NF grade, technical grade, and high-purity grade. The production route uses saponification of wool grease, solvent extraction, purification, and controlled crystallization. The site operates stainless steel saponification vessels, solvent recovery columns, and jacketed crystallization vessels with batch control of cooling rate and agitation. Production capacity supports multi-metric-ton annual output across pharmaceutical, cosmetic, diagnostic, and optical intermediate markets.

The manufacturing scope includes cholesterol NF, technical grade with gas chromatographic purity not less than 95.0% area normalization, high-purity grade above 99.0% area normalization, and low-peroxide grades for oxidation-sensitive formulations. Each lot is traceable to the wool grease campaign, saponification batch, purification column lot, crystallization vessel, and drying cycle.

How Does Cholesterol Function in Industrial Formulation and Processing?

Cholesterol is used as a C₂₇ sterol starting material for 7-dehydrocholesterol and vitamin D₃ synthesis. The purity of the cholesterol feed affects the concentration of 7-ketocholesterol and other autoxidation products after allylic oxidation. Preparative HPLC monitoring is used on the production scale to track conversion and separate unreacted cholesterol from oxidized intermediates. Low moisture content is specified because residual water can interfere with esterification and radical substitution steps in the synthetic sequence.

In skin barrier formulations, cholesterol is blended with ceramides and free fatty acids at molar ratios near 1:1:1 to support lamellar lipid phase formation. For this application, the production site supplies low-peroxide cholesterol with a peroxide value below 5.0 meq/kg and an acid value below 0.5 mg KOH/g. Autoxidation products and free acids alter the melting transition and can reduce the formation of the long-periodicity lamellar phase in finished formulations.

Diagnostic reagent manufacturers use cholesterol as a substrate and calibrator raw material in enzymatic methods. Residual peroxide from autoxidation is a controlled parameter because cholesterol oxidase methods respond to the enzymatic conversion of the substrate; interfering autoxidation products can shift calibration curves. Published cell culture media formulations commonly deliver cholesterol through lipid supplements or cyclodextrin complexes at concentrations in the range of 0.5 to 20 mg/L, with predissolution in ethanol or DMSO because free cholesterol has low aqueous solubility.

Cholesterol esters are used in cholesteric liquid crystal formulations for thermochromic films and temperature sensors. The reflected wavelength of the cholesteric phase depends on the helical pitch, which is influenced by ester composition, free cholesterol content, and temperature. Free sterol content is controlled by gas chromatography to reduce clearing point variation in downstream formulations.

Release Testing Controls Thermal, Optical, and Purity Parameters

Each batch is released against the current USP Cholesterol monograph and additional internal controls. Melting range, specific rotation, loss on drying, and residue on ignition are tested by the corresponding compendial methods. Gas chromatography with flame ionization detection is used for purity and related sterol profile. The table lists the main release specifications for NF and technical grades.

Parameter	NF grade specification	Technical grade specification	Test method
Appearance	White to faintly yellow crystalline powder	White to pale yellow powder	Visual
Melting range	147–150°C	145–150°C	USP <741>
Specific rotation	−34° to −38° (c=2, dioxane, 25°C)	−30° to −38°	USP <781>
Loss on drying	≤0.3%	≤0.5%	USP <731>
Residue on ignition	≤0.1%	≤0.2%	USP <281>
Purity by GC	≥99.0% area normalization	≥95.0% area normalization	In-house GC-FID
Peroxide value	≤5.0 meq/kg	≤10.0 meq/kg	In-house iodometric

Batch-to-batch thermal behavior is monitored by differential scanning calorimetry where required for high-purity and low-peroxide grades. Crystallization cooling rate is maintained within a defined band because a wider deviation can produce a broader particle size distribution and lower bulk density. Typical bulk density for crystalline cholesterol is controlled between 0.35 g/cm³ and 0.50 g/cm³ depending on grade. Retention samples are held for 36 months from the release date. The production site operates under ISO 9001:2015, and deviations are documented through a closed-loop investigation system.

Packaging is configured to protect the crystalline material from light, oxygen, and moisture. Standard packages are double LDPE liners inside fiber drums with net weights of 1 kg, 5 kg, and 25 kg. High-purity and low-peroxide grades are filled under nitrogen and heat-sealed. Each container is labeled with the CAS number, EC number, lot number, production date, retest date, net weight, and storage conditions. Fiber drums are conditioned to avoid moisture pickup before filling. Pallets are heat-treated to ISPM 15 for export.

Standard dispatch for stocked NF and technical grades is 5–7 working days after release. Campaign-based production for high-purity or customer-specific particle size grades is scheduled against solvent recovery capacity and typically requires 10–15 working days before release. Annual supply agreements can reserve production capacity and align batch release documentation with the receiving site’s qualification calendar.

When Technical Support Is Required for Scale-Up and Regulatory Transfer

Technical support requests are handled through the production, quality assurance, and process engineering functions. Pharmaceutical manufacturers can receive method transfer data, residual solvent profiles according to USP <467>, elemental impurities data aligned to ICH Q3D, and stability summaries based on ICH Q1A storage conditions. Cosmetic and diagnostic manufacturers can receive laser diffraction particle size distribution data, peroxide value trend reports, and solubility data in common solvent systems.

Regulatory documentation includes a certificate of analysis, safety data sheet, technical data sheet, TSE/BSE statement, allergen statement, and residual solvent declaration. Analytical method inquiries are routed to the quality control laboratory; process scale-up questions are routed to the production engineering group with access to batch records and campaign data.

Procurement value derives from direct specification control and lot-to-lot consistency. Because the manufacturing site controls saponification, crystallization, drying, and release testing, technical questions do not require intermediary interpretation. Distributors receive a controlled document set including certificate of analysis, safety data sheet, technical data sheet, and regulatory statements. Manufacturers using cholesterol in pharmaceutical intermediates, diagnostics, or cosmetic actives can align raw material specifications with process limits at the production level rather than reworking documentation from an external supply chain.

Operational boundaries are defined. Cholesterol should be stored at 15–25°C in sealed original containers protected from light. Storage above 30°C or prolonged exposure to air increases peroxide development. The material is incompatible with strong oxidizing agents and should be stored separately. Although cholesterol is not classified as dangerous goods for transport under standard modal regulations, bulk handling systems should include dust control because fine powder can form combustible dust clouds when dispersed in air.

Perguntas frequentes industriais